Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

January 31, 2006

Conditions

Atopic Dermatitis

Interventions

DRUG

Pimecrolimus

Trial Locations (2)

Novartis Investigative Site, Bonn

Novartis Investigative Site, Frankfurt am Main